Physician profile
Keyvan Yousefi
NPI 1679650386
$20,052.86
in general payments reported to CMS, 2019-2025
34 companies · $4,336 in 2025
The $4,336 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $2,188 · 2021: $3,605 · 2022: $3,402 · 2023: $2,420 · 2024: $2,441 · 2025: $4,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,506 · Consulting Fee: $1,453 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,506.18 |
| Consulting Fee | $1,452.50 |
| Education | $238.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,046.88 | 2019-2025 | Uplizna, Krystexxa, Evenity |
| Abbvie INC. | $2,435.41 | 2019-2025 | Rinvoq, Ubrelvy, Skyrizi |
| Ucb, INC. | $2,078.48 | 2020-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,879.93 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Glaxosmithkline, LLC. | $1,870.58 | 2019-2025 | Benlysta, Nucala |
| Invivyd INC | $1,452.50 | 2025 | Pemgarda |
| Horizon Therapeutics Plc | $1,356.57 | 2019-2023 | Krystexxa |
| Pfizer INC. | $753.67 | 2019-2025 | |
| Lilly USA, LLC | $716.41 | 2019-2023 | Taltz |
| Radius Health, INC. | $693.21 | 2021-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $673.12 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $607.66 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.96 | 2020-2025 | Ofev, Jardiance, Cyltezo |
| Astrazeneca Pharmaceuticals Lp | $305.67 | 2021-2024 | Saphnelo |
| Cardinal Health 110 LLC | $200.00 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $169.68 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $158.57 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $155.22 | 2019-2022 | |
| Cook Medical LLC | $125.60 | 2019 | |
| Scpharmaceuticals INC. | $117.92 | 2024 | |
| Fresenius Kabi USA, LLC | $117.49 | 2023 | Idacio |
| Sobi, INC | $92.38 | 2022-2025 | |
| Genentech USA, INC. | $86.94 | 2019-2025 | Actemra |
| Ani Pharmaceuticals, INC. | $86.00 | 2025 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company Ltd. | $73.26 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $71.13 | 2024 | Arcalyst |
| Bioventus LLC | $68.81 | 2020-2022 | |
| Zimmer Biomet Holdings, INC. | $54.65 | 2019-2020 | |
| Alvogen INC | $25.96 | 2024 | Teriparatide |
| Sandoz INC. | $23.06 | 2023 | Hyrimoz |
| Daiichi Sankyo INC. | $21.89 | 2020 | |
| Depuy Synthes Sales INC. | $21.15 | 2024 | Orthovisc |
| Novo Nordisk INC | $18.50 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keyvan Yousefi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.